A team led by researchers from Penn State College of Medicine has developed a new method that substantially improves the ability to map the genetic variants that drive disease, particularly neurodegenerative diseases.
Studying T cells, the immune cells most responsible for responding to infections and cancers, just received a significant boost in the form of a new technique from St. Jude Children’s Research Hospital
A patented RNA-based cocktail developed at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has emerged as a promising active agent against tumors of the central nervous system, such as glioblastoma.
Inside a lab in the French city of Orleans, scientists are testing out the limits of molecules in our body called messenger RNA—best known for being used in COVID-19 vaccines—in the hopes of finding a breakthrough treatment for a particularly deadly cancer.
Researchers at the Eye Genetics Research Unit at Children’s Medical Research Institute (CMRI) are the first in the world to use stem cells to study one of the genetic causes of Leber Congenital Amaurosis (LCA)—a rare condition that causes severe vision loss in babies and young children.
The immune system plays a crucial role in fighting tumors and metastases. Consequently, it is decisive to conduct cancer research in mouse models with an immune system that is as natural as possible—which is easier said than done.
A new discovery from the lab of YouYang Zhao, Ph.D., from Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago, opens promising new directions for treatment of life-threatening lung injury caused by sepsis.
In a major step forward for cancer care, researchers at ChristianaCare’s Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer. The approach restores drug sensitivity and slows tumor growth. The findings are published in the journal Molecular Therapy Oncology.
University of Kentucky researchers have developed a new experimental model that could point the way toward more effective Alzheimer’s disease treatments by targeting one of the brain’s most important genes for risk and resilience.
Scientists at The Hospital for Sick Children (SickKids) have revealed a previously overlooked layer of genetic variation that could help explain why people experience disease differently, and why some treatments work better for certain populations.